National Storage Mechanism | Additional information 
RNS Number : 5965F
Genedrive PLC
31 October 2025
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.
UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
genedrive plc
("genedrive" or the "Company")
Potential Shareholder Loan
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, today announces an update regarding discussions with David Nugent, a 16% shareholder in the Company including via a limited company.
Since the Company's general meeting on 15 October 2025 the Company has continued to engage constructively with David Nugent around financing options for the Company and to this end he has recently indicated a willingness to make a direct cash injection into the Company by way of a loan of up to £1 million on terms to be agreed between the parties. Whilst there can be no certainty that this additional funding will be received the Company welcomes this indication of potential additional financial support from David Nugent and further announcements will be made in due course.
For further details please contact:
| | |
| --- | --- |
| genedrive plc | +44 (0)161 989 0245 |
| Gino Miele: CEO / Russ Shaw: CFO | |
| | |
| Peel Hunt LLP (Nominated Adviser and Broker) | +44 (0)20 7418 8900 |
| James Steel | |
| | |
| Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or [\[email protected\]](/cdn-cgi/l/email-protection#7a1d1f141f1e08130c1f3a0d1b1618081515110a0854191517) |
| Anna Dunphy | +44 (0)7876 741 001 |
About genedrive plc (http://www.genedrive.com)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [\[email protected\]](/cdn-cgi/l/email-protection#4d3f233e0d213e282a632e2220) or visit [www.rns.com](http://www.rns.com/).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](https://www.lseg.com/privacy-and-cookie-policy).
END
MSCEADEEDFFSFAA